Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs ...

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17).

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026 SOTIO ...

ArriVent BioPharma, Inc. ( ($AVBP) ) has released its Q4 earnings. Here is a breakdown of the information ArriVent BioPharma, Inc. presented to ...

Frazier Life Sciences launched Callio Therapeutics, a cancer startup headquartered in Seattle and Singapore. Frazier led ...

The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation.

Callio Therapeutics, a biotechnology company, has launched with the closing of a $187.0 million Series A financing round.

The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. An archived replay will be available for at least 30 ...

Wedbush reaffirmed their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report ...

Elevation Oncology (NASDAQ:ELEV – Get Free Report) will likely be issuing its quarterly earnings data before the market opens ...